Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Cerity Partners LLC

Cerity Partners LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.3% in the 4th quarter, HoldingsChannel reports. The firm owned 126,834 shares of the medical research company’s stock after purchasing an additional 4,012 shares during the quarter. Cerity Partners LLC’s holdings in Edwards Lifesciences were worth $9,207,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the 4th quarter worth approximately $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth $54,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent research reports. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays upped their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $68.26 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50 day simple moving average of $71.36 and a 200 day simple moving average of $70.67. The company has a market capitalization of $40.13 billion, a PE ratio of 9.79, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,153,526.69. This trade represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,853 shares of company stock worth $4,534,247. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.